When used in combination with PD-1, tumor infiltration of Tregs is significantly reduced, and the CD8 T/Treg ratio increases (Hao et al., 2023), thereby avoiding the immune desert phenotype, which explains the effective synergy of immunogenic chemotherapeutic drugs and ICB. Here, PDCD1 is linked to neoplasm.